Extra: Can Americans Trust The US Organ Donation System?
In some cases, donors were still showing neurological signs, indicating the organ procurement process began for patients before they were officially declared deceased.
The report led to shocking headlines, a congressional hearing, and many Americans questioning whether they could trust our country's organ donation system.
Recently on the FOX News Rundown, the chief of the Health Resources and Services Administration's organ transplant branch, Dr. Raymond Lynch, joined host Jessica Rosenthal to discuss the alarming report, the process of organ transplants, and what they're doing to ensure that they're done properly.
Dr. Lynch discussed what went wrong in the cases where the transplant process began too early, but also emphasized how well the system works generally and how it's vital to saving lives.
We often have to cut interviews short during the week, but we thought you might like to hear the full interview.
Today on Fox News Rundown Extra, we will share our entire interview with Dr. Raymond Lynch, allowing you to learn even more about America's organ donation system.
Learn more about your ad choices. Visit podcastchoices.com/adchoices
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
32 minutes ago
- CBS News
Maryland woman donates kidney to her older sister: "She saved my life"
On April 1, 2025, Dr. Lisa Carchedi gave her older sister, Gina Warsaw, a kidney and a chance at a longer life. The date was important for the Maryland sisters, who are 15 years apart, because their father, who died six years ago on that day. Their father preached that family comes first and foremost. "I was willing to do it," said Carchedi, who psychiatrist at the University of Maryland Upper Chesapeake Health in Bel Air. "It was something I decided to do, and I was happy to do it." Four months later, on Sunday, Aug. 3, National Sisters Day means so much more for the siblings. "Lisa's the best, I mean, she saved my life," Warsaw said. Over the past few years, Carchedi witnessed the toll kidney failure and dialysis had on her oldest sister, and she wanted to help give her sister a second chance at life. Carchedi got tested as a possible living kidney donor, and she was a match for her sister. They went through with the donor surgery on April 1, 2025. "I kept asking, 'Are you sure? Are you sure?" Warsaw asked. "I couldn't believe my sister was going to save me from all that." Carchedi's donated kidney was removed using a minimally invasive robot-assisted technique performed by Dr. Chandra Bhati, a professor and chief of the Division of Transplant Surgery at the University of Maryland Medical Center (UMMC) in Baltimore. "We just made a 17-centimeter incision and did a single port, which means the one incision, and the whole surgery was done through that single port, and that incision was around the belly button," Dr. Chandra Bhati said. Bhati explained that this technique reduces scarring and speeds up recovery time for kidney donors. "There are only a handful of surgeons across the country who actually use this robot to do the surgery. So we are one of those few centers who does this," Bhati said. The sisters have been close throughout their lives: Warsaw helped take care of Carchedi and her siblings as they grew up. Carchedi returned the favor in high school by babysitting Warsaw's four children and watching them grow into parents. "I don't have my own biological children, so I told my nieces and nephews that I did this for them, and their kids, that it was my gift to them," said Carchedi. "You know that they would have more years and they would have more years with Gina." Warsaw said that the kidney donation is something of a role reversal. "Now I feel like she's my big sister, I'm the helpless one now," Warsaw said. Warsaw's husband, Lewis Warsaw, says he can't imagine a gift greater than what was given to his wife. "In Hebrew, you'd call it a mitzvah when someone gives you something as valuable as this, and the mitzvah is coming from Lisa to Gina," Lewis Warsaw said. Post-transplant recovery continues to go well for both sisters. "I don't know what else she can put on her resume, but now she can put I am a kidney donor too," Warsaw said. Warsaw explained to WJZ that she's slowly regaining strength and getting back to doing some of the things she likes to do, including spending time with her grandchildren. Carchedi took a few days off from work and is now back on the job as a psychiatrist at UM Upper Chesapeake Health's Klein Family Center. In another post-transplant event, Carchedi's then-boyfriend, Dave Cosgrove, whom she met through their shared hobby of amateur ballroom dancing, has proposed to her. They plan to get married in November.
Yahoo
an hour ago
- Yahoo
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
an hour ago
- Yahoo
Option Care Health, Inc. (OPCH): A Bull Case Theory
We came across a bullish thesis on Option Care Health, Inc. on Brian's Substack by Brian Flasker. In this article, we will summarize the bulls' thesis on OPCH. Option Care Health, Inc.'s share was trading at $29.35 as of July 31st. OPCH's trailing and forward P/E were 23.29 and 19.65, respectively according to Yahoo Finance. A home infusion nurse in full PPE gown delivering treatments to a patient in their own home. Option Care Health (OPCH) has evolved into the dominant independent provider of home and alternate site infusion services in the U.S., originating from Madison Dearborn Partners' 2015 acquisition of Walgreens Infusion Services. The 2019 reverse merger with BioScrip and full divestiture by Walgreens and MDP by 2023 paved the way for OPCH to operate with full independence. Led by CEO John Rademacher and CFO Michael Shapiro, both with substantial equity stakes, OPCH has built a national infrastructure of 91 pharmacies and 99 infusion suites, covering 96% of the U.S. population. The company's integrated model provides cost-effective, high-quality infusion therapies in outpatient and home settings, capitalizing on a healthcare trend shifting treatments away from costly hospitals. This platform serves over 1,400 contracts with 800+ partners, including all top 10 national insurers. Acute therapies, though operationally complex, act as a competitive wedge, while chronic therapies anchor long-term recurring revenues. OPCH's mix—75% chronic, 25% acute—combined with a focus on generics and biosimilars, ensures resilience against pricing volatility. With its Advanced Practitioner (AP) model, OPCH is pushing clinical boundaries, managing more complex therapies in lower-cost settings and enhancing utilization of its already-built infrastructure. Only ~50% of its infusion suite capacity is currently utilized, leaving ample runway for capital-light growth. Despite industry concerns like drug pricing reforms and labor shortages, OPCH's embedded relationships, clinical capabilities, and scalable model offer strong visibility into cash flow and earnings. Trading at ~15.4x 2025 owner earnings with a 17.4% expected IRR, OPCH represents a high-quality compounder with an entrenched moat and significant upside. Previously, we covered a bullish thesis on Chemed Corporation by 310 Value in April 2025, which highlighted the durability of its earnings, temporary volatility in its subsidiaries, and disciplined share repurchases. The company's stock price has depreciated by approximately 29% since our coverage. This is because temporary segment headwinds persisted longer than expected. The thesis still stands as Chemed's core fundamentals remain intact. Brian Flasker shares a similar view but emphasizes OPCH's capital-light model and payer-aligned infrastructure. Option Care Health, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held OPCH at the end of the first quarter, which was 40 in the previous quarter. While we acknowledge the potential of OPCH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
